Want to join the conversation?
$ABBV will pay Stemcentrx about $2Bil of the transaction value in cash and fund the remaining portion with stock. Stemcentrx investors are eligible to receive up to $4Bil in cash for additional, success-based milestone payments for the achievement of some regulatory and clinical developments. $ABBV expects the deal to close in 2Q16.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.